Digital Pathology in Accelerating Drug Development

| November 26, 2018

article image
Tissue pathology is at the core of various aspects of the pharmaceutic pipeline. Digital pathology is a technology that converts glass microscope slides with tissue samples into whole slide digital images, which can be used to identify, quantify, and document key characteristics of tissue samples. This opens up a new world of applications that can potentially improve and accelerate pharmaceutic development.

Spotlight

Ottobock

All over the world, the name Ottobock is a synonym for high-quality and technologically outstanding medical technology products and services. The goal of helping to restore mobility to people with disabilities, and protect what mobility they have, stands behind each and every one of the company's products. Our conviction that quality of life is closely connected to a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company's nearly 100-year history and guides the development of new products in a focused manner.

OTHER ARTICLES

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 11, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Spotlight

Ottobock

All over the world, the name Ottobock is a synonym for high-quality and technologically outstanding medical technology products and services. The goal of helping to restore mobility to people with disabilities, and protect what mobility they have, stands behind each and every one of the company's products. Our conviction that quality of life is closely connected to a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company's nearly 100-year history and guides the development of new products in a focused manner.

Events